Study finds Ulesfia effectively kills head lice
HOBOKEN, N.J. A new non-neurotoxic treatment for head lice has been found to have an average of 91.2% treatment success rate after one week, and to be safe in humans from 6 months of age and up, according to a study published in the latest issue of Pediatric Dermatology.
Benzyl Alcohol Lotion 5% (branded Ulesfia) works by suffocating lice. Unlike commonly used asphyxiant remedies, scanning electron microscopy appears to indicate that benzyl alcohol lotion effectively asphyxiates lice by “stunning” the spiracles open, allowing the lotion, comprised of mineral oil and other inactive ingredients, to infiltrate the “honeycomb” respiratory apparatus and kill lice.
“Existing over-the-counter head lice treatments contain neurotoxic pesticides as active ingredients, resulting in potential toxicity and other problems, including lengthy applications, odor, ineffective treatment,” stated study author Terri Meinking of Global Health Associates. “Resistance has also become a problem now that lice have had such prolonged exposure to these products.”
Stopain partners with Arthritis Foundation
ENCINITAS, Calif. DRJ Group, the makers of Stopain topical analgesics, on Tuesday announced that new product packaging labels showing the company’s support for the Arthritis Foundation will begin appearing on store shelves.
The labels read, in part, “Your purchase benefits the Arthritis Foundation. For every unit of Stopain products sold, DRJ Group will donate a portion of the proceeds to the Arthritis Foundation with a minimum contribution of $25,000 to help people take control of arthritis.”
The new label messaging is part the company’s year-long awareness and fundraising initiative with the Arthritis Foundation.
As part of the initiative, DRJ Group released a video in cooperation with the Arthritis Foundation –– Stop Pain. Start Dancing –– which stars motivational speaker and dancer, Judson Laipply. The video was designed to help spread the message that staying active has long-term health benefits, including managing the effects of arthritis.
E-cigarette maker welcomes FDA challenge
MIAMI Despite the ongoing battle between the Food and Drug Administration and electronic cigarette makers, one manufacturer welcomes the challenge as a chance to present its product as a healthier alternative to traditional tobacco.
Green Smoke said it has created an electronic cigarette designed to simulate the smoking experience without carcinogenics. Instead, it emits an odorless vapor of mostly steam, with ingredients like nicotine, water, propylene glycol (an additive used in cake mixes) and others. The nicotine also is available in different strengths.
The company also added that the price for the electronic cigarettes are more cost-efficient than regular tobacco products, with cigarette starter kits ranging from $109 to $270. The starter kits include nicotine cartridges, rechargeable cigarette batteries, home charger and more.